Encefalitis por anticuerpos contra el receptor de NMDA. Reporte de un caso y revisión de la literatura;
Encefalite causada por anticorpos contra o receptor nmda. Relatório de caso e revisão da literatura

dc.creatorForero, Edwin
dc.creatorCastro Vargas, Hernán
dc.date2020-07-01
dc.date2023-03-22T19:09:44Z
dc.date2023-03-22T19:09:44Z
dc.date.accessioned2023-09-06T17:40:03Z
dc.date.available2023-09-06T17:40:03Z
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/4846
dc.identifier10.18359/rmed.4846
dc.identifierhttp://hdl.handle.net/10654/43508
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8692103
dc.descriptionAnti-nmda receptor encephalitis is a severe, treatable, and potentially reversible disorder characterized by the presence of behavioral disturbances, seizures, and movement disorders. The presence of antibodies against the glutamate receptor (anti-nmda) in plasma or cerebrospinal fluid is specific to the diagnosis of the disease. Early recognition of the disease is vital for the patient’s prognosis since early management facilitates recovery and reduction of morbidity and mortality. Treatment consists of corticosteroids, intravenous immunoglobulin, or plasmapheresis as the first line of therapy, in addition to other immunomodulators, such as cyclophosphamide or rituximab, as the second line. Recovery is slow but improves as antibody titers decrease. Complete recovery occurs in up to 75 % of patients.
dc.descriptionLa encefalitis por anticuerpos contra el receptor de nmda es un desorden grave, tratable y potencialmente reversible, caracterizado por la presencia de alteraciones en el comportamiento, convulsiones y trastornos del movimiento. La presencia de anticuerpos contra el receptor del glutamato (anti-nmda) en plasma o líquido cefalorraquídeo es específico para el diagnóstico de la enfermedad. El reconocimiento temprano de la enfermedad es vital para el pronóstico del paciente, dado que el manejo precoz facilita la recuperación y reducción de la morbimortalidad. El tratamiento consiste en la utilización de corticoides, inmunoglobulina intravenosa o plasmaféresis como primera línea de terapia; además de otros inmunomoduladores, como ciclofosfamida o rituximab, como segunda línea. La recuperación es lenta, pero presenta mejoría en la medida en que los títulos de anticuerpos disminuyen y llega a una recuperación completa hasta en 75 % de los pacientes.
dc.descriptionA encefalite causada por anticorpos contra o receptor nmda é um distúrbio grave, tratável e potencialmente reversível, caracterizado pela presença de alterações comportamentais, convulsões e transtornos de movimento. A presença de anticorpos contra o receptor de glutamato (anti-nmda) no plasma ou no líquido cefalorraquidiano é específica para o diagnóstico da doença. O reconhecimento precoce da doença é vital para o prognóstico do paciente, visto que o tratamento precoce facilita a recuperação e a redução da morbimortalidade. O tratamento consiste no uso de corticoides, imunoglobulina intravenosa ou plasmaférese como primeira linha de terapia. Além de outros imunomoduladores, como ciclofosfamida ou rituximabe, como segunda linha. A recuperação é lenta, mas apresenta melhora à medida que os títulos de anticorpos diminuem e a recuperação completa ocorre em até 75% dos pacientes.
dc.formattext/xml
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/4846/3951
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/4846/4118
dc.relation/*ref*/Vitaliani R, Mason W, Ances B, Zwerdling T, Jian Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005; 58(4):594-604.
dc.relation/*ref*/PMid:16178029 PMCid:PMC2245881
dc.relation/*ref*/Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Dessain SK et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7(12):1091-8.
dc.relation/*ref*/Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009; 66(1):11-8.
dc.relation/*ref*/PMid:19670433 PMCid:PMC2826225
dc.relation/*ref*/Dalmau J, Lancaster E, Martínez-Hernández E, Rosenfeld M. Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10(1):63-74.
dc.relation/*ref*/Armangue T. Petit-Pedrol, Mar. Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012; 27(11):1460-9.
dc.relation/*ref*/PMid:22935553 PMCid:PMC3705178
dc.relation/*ref*/Glaser C, Iizuka T, Honig LS, Aguilar E, Gresa N, Ryan N et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol. 2014; 12(2):157-65.
dc.relation/*ref*/Warren N, Grote V, Gorman CO, Siskind D. Electroconvulsive therapy for anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: A systematic review of cases. Brain Stimul. 2018; 12(2):329-34. Doi: https:// doi.org/10.1016/j.brs.2018.11.016
dc.relation/*ref*/PMid:30528383
dc.relation/*ref*/Khundakji Y, Masri A, Khuri N. Anti-NMDA receptor encephalitis in a toddler: A diagnostic challenge. Int J Pediatr Adolesc Med. 2018; 5(2):75-7. Doi: https://doi. org/10.1016/j.ijpam.2018.03.001
dc.relation/*ref*/PMid:30805537 PMCid:PMC6363247
dc.relation/*ref*/Guasp M, Dalmau J. Encefalitis por anticuerpos contra el receptor de NMDA. Med Clin (Barc). 2018; 151(2):71- 9. Doi: https://doi.org/10.1016/j.medcli.2017.10.015
dc.relation/*ref*/PMid:29183618
dc.relation/*ref*/Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D et al. Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study. Lancet Infect Dis. 2010; 10(12):835-44. Doi: http://dx.doi.org/10.1016/S1473-3099(10)70222-X
dc.relation/*ref*/Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012; 54:899-904.
dc.relation/*ref*/PMid:22281844 PMCid:PMC3297648
dc.relation/*ref*/Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr. 2010; 22:739-44.
dc.relation/*ref*/PMid:21045695
dc.relation/*ref*/Wandinger K, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011; 231(1-2):86-91. Doi: http://dx.doi.org/10.1016/j.jneuroim.2010.09.012
dc.relation/*ref*/PMid:20951441
dc.relation/*ref*/Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014; 36(8):645-52. Doi: http://dx.doi.org/10.1016/j.braindev.2013.10.005
dc.relation/*ref*/PMid:24211006
dc.relation/*ref*/Jones KC, Benseler SM. Anti-NMDA receptor encephalitis. Neuroimaging Clin N Am. 2013; 23(2):309-20. Doi: http://dx.doi.org/10.1016/j.nic.2012.12.009
dc.relation/*ref*/PMid:23608692
dc.relation/*ref*/Consoli A, Ronen K, An-gourfinkel I, Barbeau M, Marra D, Costedoat N et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: Case report. Child Adolescent Psychiatry Ment Heal. 2011; 5(15):2-7.
dc.relation/*ref*/PMid:21569502 PMCid:PMC3121673
dc.relation/*ref*/Kurian M, Lalive P, Dalmau J, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol. 2010; 67(1):1-5.
dc.relation/*ref*/PMid:20065141 PMCid:PMC2819405
dc.relation/*ref*/Agundez M, Mendibe M, Carlos J, Ciordia R, Saiz A, Zarranz JJ. Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis. J Neurol. 2010; 257:1568-9.
dc.relation/*ref*/PMid:20352245
dc.relation/*ref*/Peery HE, Day GS, Dunn S, Fritzler MJ, Prüss H, Souza C et al. Autoimmunity reviews anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev. 2012;11(12):863-72. Doi: http://dx.doi.org/10.1016/j.autrev.2012.03.001
dc.relation/*ref*/PMid:22440397
dc.relation/*ref*/Wong-Kisiel LC, Ji T, Renaud DL, Kotagal S, Patterson MC, Dalmau J et al. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology. 2010; 74:1550-1.
dc.relation/*ref*/PMid:20458074 PMCid:PMC2875922
dc.rightsDerechos de autor 2020 Revista Med
dc.sourceRevista Med; Vol. 27 No. 2 (2019): july - december; 113-120
dc.sourceRevista Med; Vol. 27 Núm. 2 (2019): julio - diciembre; 113-120
dc.source1909-7700
dc.source0121-5256
dc.titleAnti-nmda receptor encephalitis. Case Report and Literature Review
dc.titleEncefalitis por anticuerpos contra el receptor de NMDA. Reporte de un caso y revisión de la literatura
dc.titleEncefalite causada por anticorpos contra o receptor nmda. Relatório de caso e revisão da literatura
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución